Windlas Biotech Ltd

Windlas Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Windlas Biotech Ltd

₹ 930 -2.89%
21 Nov 4:00 p.m.
windlasbiotech.com BSE: 543329 NSE: WINDLAS
About

Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.[1]

Key Points

Market Position
Windlas Biotech is amongst the top five players in the domestic pharmaceutical formulations, contract development, and manufacturing organization (CDMO) industry in India, in terms of revenues. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics. [1]

Website BSE NSE
  • Market Cap ₹ 1,946 Cr.
  • Current Price ₹ 930
  • High / Low ₹ 1,198 / 398
  • Stock P/E 31.8
  • Book Value ₹ 225
  • Dividend Yield 0.59 %
  • ROCE 18.2 %
  • ROE 13.7 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 21.2% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 19.8%
  • Company's working capital requirements have reduced from 65.3 days to 32.8 days

Cons

  • Company has a low return on equity of 12.3% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Part of BSE Healthcare BSE Allcap BSE SmallCap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
115 118 122 120 133 120 141 145 153 162 171 175 187
102 105 108 106 117 106 124 128 134 142 149 154 164
Operating Profit 13 13 14 14 16 14 16 17 19 20 22 21 23
OPM % 11% 11% 11% 12% 12% 12% 12% 12% 12% 13% 13% 12% 12%
1 2 3 3 3 2 2 3 3 3 4 4 5
Interest 0 0 0 0 0 0 0 0 0 0 0 0 1
Depreciation 3 3 3 3 3 3 4 3 3 3 4 6 6
Profit before tax 11 11 14 14 16 13 15 16 18 20 23 18 20
Tax % 24% 28% -8% 28% 22% 28% 24% 26% 23% 24% 25% 26% 23%
8 8 15 10 12 9 11 12 14 15 17 13 16
EPS in Rs 3.81 3.81 6.79 4.50 5.59 4.26 5.38 5.80 6.75 7.26 8.17 6.45 7.49
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
352 307 329 428 466 513 631 696
313 270 295 373 414 453 553 609
Operating Profit 39 38 34 55 52 60 78 86
OPM % 11% 12% 10% 13% 11% 12% 12% 12%
4 54 2 -19 7 10 13 17
Interest 6 5 3 1 1 1 1 2
Depreciation 17 11 9 13 12 12 13 20
Profit before tax 20 76 25 22 46 57 77 81
Tax % 44% 16% 34% 28% 16% 25% 25%
11 64 16 16 38 43 58 61
EPS in Rs 20.04 99.55 25.28 24.69 17.48 20.04 27.98 29.37
Dividend Payout % 0% 0% 0% 0% 20% 20% 20%
Compounded Sales Growth
10 Years: %
5 Years: 15%
3 Years: 14%
TTM: 25%
Compounded Profit Growth
10 Years: %
5 Years: 21%
3 Years: 23%
TTM: 31%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 49%
1 Year: 111%
Return on Equity
10 Years: %
5 Years: 12%
3 Years: 12%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 6 6 6 6 11 10 10 10
Reserves 119 187 203 193 384 392 440 461
57 32 29 32 7 5 4 19
107 73 100 65 90 122 173 257
Total Liabilities 290 298 338 296 491 529 626 747
86 64 70 96 91 109 179 188
CWIP 53 5 0 0 8 15 6 31
Investments 23 122 116 23 65 107 173 182
128 107 152 177 327 298 268 346
Total Assets 290 298 338 296 491 529 626 747

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
35 19 25 11 9 61 109
-11 -7 -14 -20 -155 -14 -92
-26 -6 -5 1 130 -44 -15
Net Cash Flow -2 6 5 -8 -15 3 2

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 69 73 71 68 87 83 79
Inventory Days 54 36 85 55 71 84 57
Days Payable 130 110 143 53 76 98 121
Cash Conversion Cycle -7 -1 13 70 81 69 15
Working Capital Days -5 9 26 66 90 73 33
ROCE % 15% 12% 19% 15% 14% 18%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
59.95% 59.95% 59.95% 59.95% 60.75% 62.37% 62.82% 62.82% 62.82% 62.82% 62.51% 62.51%
3.77% 3.40% 3.21% 2.19% 1.45% 1.32% 0.80% 0.80% 1.35% 1.18% 1.59% 2.00%
11.30% 9.83% 12.23% 11.14% 12.20% 11.61% 11.53% 11.52% 11.71% 11.82% 10.35% 9.58%
24.99% 26.82% 24.62% 26.71% 25.59% 24.68% 24.84% 24.85% 24.11% 24.19% 25.55% 25.91%
No. of Shareholders 99,27192,11588,74686,80182,69079,23375,47068,79861,90051,27745,82445,706

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls